Fax: (212) 639-2417
Original Article
You have full text access to this OnlineOpen article
Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma†
Article first published online: 18 JAN 2006
DOI: 10.1002/cncr.21683
Copyright © 2006 American Cancer Society
Additional Information
How to Cite
Chen, W. C., Jackson, A., Budnick, A. S., Pfister, D. G., Kraus, D. H., Hunt, M. A., Stambuk, H., Levegrun, S. and Wolden, S. L. (2006), Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer, 106: 820–829. doi: 10.1002/cncr.21683
- †
Presented in part at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), October 16, 2005, Denver, Colorado.
- ‡
Fax: (212) 639-2417
Publication History
- Issue published online: 3 FEB 2006
- Article first published online: 18 JAN 2006
- Manuscript Accepted: 20 SEP 2005
- Manuscript Revised: 21 AUG 2005
- Manuscript Received: 23 MAY 2005
Funded by
- Tomorrow Foundation
- National Cancer Institute. Grant Number: PO1–CA–59017
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , Human ultrasonic hearing is induced by a direct ultrasonic stimulation of the cochlea, Neuroscience Letters, 2013, 539, 71
- 2, , , , Risk of developing sudden sensorineural hearing loss in patients with nasopharyngeal carcinoma: A population-based cohort study, Head & Neck, 2013, 35, 6Direct Link:
- 3, , , , , , Long-Term Hearing Results and Otological Complications of Nasopharyngeal Carcinoma Patients: Comparison between Treatment with Conventional Two-Dimensional Radiotherapy and Intensity-Modulated Radiotherapy, ORL, 2012, 74, 4, 228
- 4, , , , , siRNA-mediated knock-down of NOX3: therapy for hearing loss?, Cellular and Molecular Life Sciences, 2012, 69, 14, 2429
- 5, , , , , The effect of resveratrol on the prevention of cisplatin ototoxicity, European Archives of Oto-Rhino-Laryngology, 2012, 269, 10, 2185
- 6, , , , , , , , , , , , , Feasibility of Tomotherapy to spare the cochlea from excessive radiation in head and neck cancer, Oral Oncology, 2011, 47, 5, 414
- 7, , , , , , , , Hearing impairment after platinum-based chemotherapy in childhood, Pediatric Blood & Cancer, 2011, 56, 4Direct Link:
- 8, , , , , , Incidence of long-term ipsilateral and contralateral ototoxicity following radiotherapy for nasopharyngeal carcinoma, Auris Nasus Larynx, 2011, 38, 1, 95
- 9, , , Organ-sparing radiation therapy for head and neck cancer, Nature Reviews Clinical Oncology, 2011, 8, 11, 639
- 10
- 11, , , , , , , Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients, Radiation Oncology, 2011, 6, 1, 19
- 12, , , , , , , The design and screening of drugs to prevent acquired sensorineural hearing loss, Expert Opinion on Drug Discovery, 2011, 6, 5, 491
- 13, , , , Cisplatinum ototoxicity in children, long-term follow up, International Journal of Pediatric Otorhinolaryngology, 2010, 74, 8, 913
- 14, , , , , , , , Distortion-Product Otoacoustic Emission Test Performance for Ototoxicity Monitoring, Ear and Hearing, 2010, 1
- 15, , Dose de tolérance à l’irradiation des tissus sains : l’oreille, Cancer/Radiothérapie, 2010, 14, 4-5, 284
- 16, , , , , , , Long term hearing degeneration after platinum-based chemotherapy in childhood, International Journal of Audiology, 2010, 49, 10, 765
- 17, , , , , , , , Ototoxicity After Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy in Children With Medulloblastoma, International Journal of Radiation Oncology*Biology*Physics, 2010, 78, 5, 1445
- 18, , , , , , , Ototoxicity in children receiving cisplatin chemotherapy, Korean Journal of Pediatrics, 2010, 53, 2, 210
- 19, , , , , , , Prospective study of sensorineural hearing loss following radiotherapy for nasopharyngeal carcinoma, The Journal of Laryngology & Otology, 2010, 124, 01, 32
- 20, , , , , , , Radiation Therapy and Hearing Loss, International Journal of Radiation Oncology*Biology*Physics, 2010, 76, 3, S50
- 21
- 22, , , , , , , Late complications of radiotherapy for nasopharyngeal carcinoma, Auris Nasus Larynx, 2009, 36, 2, 205
- 23, , , , , , , , Ototoxicity after combined platinum and fractionated radiation in a novel guinea pig model, American Journal of Otolaryngology, 2009, 30, 1, 1
- 24, , , , , Relative Contributions of Radiation and Cisplatin-Based Chemotherapy to Sensorineural Hearing Loss in Head-and-Neck Cancer Patients, International Journal of Radiation Oncology*Biology*Physics, 2009, 73, 3, 779
- 25, , , , , , , Risk Factors for Hearing Loss in Patients Treated With Intensity-Modulated Radiotherapy for Head-and-Neck Tumors, International Journal of Radiation Oncology*Biology*Physics, 2009, 74, 2, 490
- 26, , , , , , , , Sensorineural Hearing Loss After Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis, International Journal of Radiation Oncology*Biology*Physics, 2009, 73, 5, 1335
- 27
- 28, , , , , , , , Brain-sparing radiotherapy for neuroblastoma skull metastases, Pediatric Blood & Cancer, 2008, 50, 6Direct Link:
- 29, , , , , Hearing Loss After Radiotherapy for Pediatric Brain Tumors: Effect of Cochlear Dose, International Journal of Radiation Oncology*Biology*Physics, 2008, 72, 3, 892
- 30, Mechanisms of cisplatin ototoxicity and progress in otoprotection, Current Opinion in Otolaryngology & Head and Neck Surgery, 2007, 15, 5, 364
- 31, , , , Mechanisms of cisplatin-induced ototoxicity and prevention, Hearing Research, 2007, 226, 1-2, 157
- 32, , , Otological Toxicity After Postoperative Radiotherapy for Parotid Tumours, Clinical Oncology, 2007, 19, 1, 77
- 33, , , , SYMPTOMATIC CHIARI TYPE I MALFORMATION AFTER RADIATION THERAPY IN AN INFANT, Neurosurgery, 2007, 60, 4, E782

1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470)